# Intra-Cellular Therapies Inc. (ITCI)

Source: https://www.quantisnow.com/company/ITCI
Generated: 2026-11-19T06:01:33.956Z

- Ticker: ITCI
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- Website: intracellulartherapies.com

## About

Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases, and other disorders of the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also developing lumateperone, which is in Phase 3 clinical trials for the treatment of bipolar depression, as well as to treat autism spectrum disorder, and sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing ITI-002 that inhibits the enzyme phosphodiesterase type 1; ITI-214 for the treatment of Parkinson's disease and heart failure; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333, for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. is headquartered in New York, New York.

## Latest ITCI news and filings

- 2025-05-01 11:00 UTC [Earnings Date] [Phathom Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update](https://www.quantisnow.com/insight/phathom-pharmaceuticals-reports-first-quarter-2025-financial-results-and-provides-6011942)
- 2025-04-14 12:55 UTC [SEC Form 15-12G filed by Intra-Cellular Therapies Inc.](https://www.quantisnow.com/insight/sec-form-15-12g-filed-by-intra-cellular-therapies-inc-5986407)
- 2025-04-10 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Intra-Cellular Therapies Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-intra-cellular-therapies-inc-5983410)
- 2025-04-03 00:34 UTC [SEC Form 4] [Director Salas Eduardo Rene returned $206,844 worth of shares to the company (1,567 units at $132.00), closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-salas-eduardo-rene-returned-206844-worth-of-shares-to-5974091)
- 2025-04-02 21:47 UTC [SEC Form 4] [Director Riggs Rory B returned $17,359,584 worth of shares to the company (131,512 units at $132.00), closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-riggs-rory-b-returned-17359584-worth-of-shares-to-5973591)
- 2025-04-02 21:46 UTC [SEC Form 4] [President Halstead Michael returned $2,812,524 worth of shares to the company (21,307 units at $132.00), closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/president-halstead-michael-returned-2812524-worth-of-shares-to-the-5973584)
- 2025-04-02 21:43 UTC [SEC Form 4] [Director Van Nostrand Robert L returned $1,496,880 worth of shares to the company (11,340 units at $132.00), closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-van-nostrand-robert-l-returned-1496880-worth-of-shares-5973570)
- 2025-04-02 21:41 UTC [SEC Form 4] [EVP, Chief Commercial Officer Neumann Mark returned $6,971,052 worth of shares to the company (52,811 units at $132.00), closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/evp-chief-commercial-officer-neumann-mark-returned-6971052-worth-of-5973551)
- 2025-04-02 21:32 UTC [SEC Form 4] [Director Marcus Joel S returned $7,687,416 worth of shares to the company (58,238 units at $132.00), closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-marcus-joel-s-returned-7687416-worth-of-shares-to-5973494)
- 2025-04-02 21:30 UTC [SEC Form 4] [Chairman and CEO Mates Sharon returned $149,851,020 worth of shares to the company (1,135,235 units at $132.00), closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/chairman-and-ceo-mates-sharon-returned-149851020-worth-of-shares-5973487)
- 2025-04-02 21:30 UTC [SEC Form 4] [EVP, Chief Medical Officer Durgam Suresh K. returned $5,664,516 worth of shares to the company (42,913 units at $132.00), closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/evp-chief-medical-officer-durgam-suresh-k-returned-5664516-worth-5973481)
- 2025-04-02 21:30 UTC [SEC Form 4] [SEC Form 4 filed by Executive Vice President & CFO Narula Sanjeev](https://www.quantisnow.com/insight/sec-form-4-filed-by-executive-vice-president-cfo-narula-5973479)
- 2025-04-02 20:32 UTC [SEC Form POSASR filed by Intra-Cellular Therapies Inc.](https://www.quantisnow.com/insight/sec-form-posasr-filed-by-intra-cellular-therapies-inc-5972886)
- 2025-04-02 20:23 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Intra-Cellular Therapies Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-intra-cellular-therapies-inc-5972715)
- 2025-04-02 20:21 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Intra-Cellular Therapies Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-intra-cellular-therapies-inc-5972690)
- 2025-04-02 20:20 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Intra-Cellular Therapies Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-intra-cellular-therapies-inc-5972677)
- 2025-04-02 20:19 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Intra-Cellular Therapies Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-intra-cellular-therapies-inc-5972664)
- 2025-04-02 20:18 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Intra-Cellular Therapies Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-intra-cellular-therapies-inc-5972622)
- 2025-04-02 20:13 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Intra-Cellular Therapies Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-intra-cellular-therapies-inc-5972456)
- 2025-04-02 20:12 UTC [SEC Form POS AM filed by Intra-Cellular Therapies Inc.](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-intra-cellular-therapies-inc-5972421)
- 2025-04-02 20:10 UTC [SEC Form 8-K] [Intra-Cellular Therapies Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Completion of Acquisition or Disposition of Assets](https://www.quantisnow.com/insight/intra-cellular-therapies-inc-filed-sec-form-8-k-notice-of-delisting-5972382)
- 2025-04-02 13:02 UTC [SEC Form 25-NSE filed by Intra-Cellular Therapies Inc.](https://www.quantisnow.com/insight/sec-form-25-nse-filed-by-intra-cellular-therapies-inc-5971435)
- 2025-03-31 22:01 UTC [SEC Form 4] [Chairman and CEO Mates Sharon gifted 190,000 shares and received a gift of 190,000 shares, decreasing direct ownership by 17% to 945,235 units (SEC Form 4)](https://www.quantisnow.com/insight/chairman-and-ceo-mates-sharon-gifted-190000-shares-and-received-5967937)
- 2025-03-27 20:08 UTC [SEC Form 8-K] [SEC Form 8-K filed by Intra-Cellular Therapies Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-intra-cellular-therapies-inc-5963057)
- 2025-03-20 21:29 UTC [SEC Form 10-K] [Amendment: SEC Form 10-K/A filed by Intra-Cellular Therapies Inc.](https://www.quantisnow.com/insight/amendment-sec-form-10-ka-filed-by-intra-cellular-therapies-inc-5954917)
- 2025-03-18 21:20 UTC [SEC Form 8-K] [SEC Form 8-K filed by Intra-Cellular Therapies Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-intra-cellular-therapies-inc-5950549)
- 2025-03-18 20:26 UTC [SEC Form 144] [SEC Form 144 filed by Intra-Cellular Therapies Inc.](https://www.quantisnow.com/insight/sec-form-144-filed-by-intra-cellular-therapies-inc-5949987)
- 2025-03-10 22:01 UTC [SEC Form 4] [Chairman and CEO Mates Sharon converted options into 61,278 shares and covered exercise/tax liability with 29,977 shares, increasing direct ownership by 3% to 1,135,235 units (SEC Form 4)](https://www.quantisnow.com/insight/chairman-and-ceo-mates-sharon-converted-options-into-61278-shares-5936671)
- 2025-03-10 22:01 UTC [SEC Form 4] [President Halstead Michael converted options into 20,478 shares and covered exercise/tax liability with 10,475 shares, increasing direct ownership by 88% to 21,307 units (SEC Form 4)](https://www.quantisnow.com/insight/president-halstead-michael-converted-options-into-20478-shares-and-covered-5936670)
- 2025-03-10 22:01 UTC [SEC Form 4] [EVP, Chief Medical Officer Durgam Suresh K. converted options into 20,478 shares and covered exercise/tax liability with 8,688 shares, increasing direct ownership by 38% to 42,913 units (SEC Form 4)](https://www.quantisnow.com/insight/evp-chief-medical-officer-durgam-suresh-k-converted-options-into-5936667)
- 2025-03-10 22:01 UTC [SEC Form 4] [EVP, Chief Commercial Officer Neumann Mark converted options into 20,478 shares and covered exercise/tax liability with 8,688 shares, increasing direct ownership by 29% to 52,811 units (SEC Form 4)](https://www.quantisnow.com/insight/evp-chief-commercial-officer-neumann-mark-converted-options-into-20478-5936666)
- 2025-03-07 22:01 UTC [SEC Form DFAN14A] [SEC Form DFAN14A filed by Intra-Cellular Therapies Inc.](https://www.quantisnow.com/insight/sec-form-dfan14a-filed-by-intra-cellular-therapies-inc-5933987)
- 2025-03-04 23:01 UTC [SEC Form 4] [President Halstead Michael covered exercise/tax liability with 6,261 shares and converted options into 12,239 shares, increasing direct ownership by 112% to 11,304 units (SEC Form 4)](https://www.quantisnow.com/insight/president-halstead-michael-covered-exercisetax-liability-with-6261-shares-and-5925506)
- 2025-03-04 23:01 UTC [SEC Form 4] [EVP, Chief Medical Officer Durgam Suresh K. covered exercise/tax liability with 3,709 shares and converted options into 8,742 shares, increasing direct ownership by 19% to 31,123 units (SEC Form 4)](https://www.quantisnow.com/insight/evp-chief-medical-officer-durgam-suresh-k-covered-exercisetax-liability-5925503)
- 2025-03-04 23:01 UTC [SEC Form 4] [Chairman and CEO Mates Sharon converted options into 34,969 shares and covered exercise/tax liability with 16,978 shares, increasing direct ownership by 2% to 1,103,934 units (SEC Form 4)](https://www.quantisnow.com/insight/chairman-and-ceo-mates-sharon-converted-options-into-34969-shares-5925499)
- 2025-03-04 23:01 UTC [SEC Form 4] [EVP, Chief Commercial Officer Neumann Mark covered exercise/tax liability with 3,709 shares and converted options into 8,742 shares, increasing direct ownership by 14% to 41,021 units (SEC Form 4)](https://www.quantisnow.com/insight/evp-chief-commercial-officer-neumann-mark-covered-exercisetax-liability-with-5925496)
- 2025-03-03 13:00 UTC [SEC Form 8-K] [SEC Form 8-K filed by Intra-Cellular Therapies Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-intra-cellular-therapies-inc-5919206)
- 2025-02-26 23:01 UTC [SEC Form 4] [Director Marcus Joel S exercised 7,009 shares at a strike of $63.79, increasing direct ownership by 17% to 48,238 units (SEC Form 4)](https://www.quantisnow.com/insight/director-marcus-joel-s-exercised-7009-shares-at-a-strike-5912363)
- 2025-02-25 22:21 UTC [SEC Form DFAN14A] [SEC Form DFAN14A filed by Intra-Cellular Therapies Inc.](https://www.quantisnow.com/insight/sec-form-dfan14a-filed-by-intra-cellular-therapies-inc-5909216)
- 2025-02-24 12:10 UTC [Analyst Downgrade] [Intra-Cellular Therapies downgraded by Mizuho with a new price target](https://www.quantisnow.com/insight/intra-cellular-therapies-downgraded-by-mizuho-with-a-new-price-target-5904333)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/ITCI
- Earnings history: https://www.quantisnow.com/earnings/ITCI
- Dividend history: https://www.quantisnow.com/dividends/ITCI
- Insider transactions: https://www.quantisnow.com/insiders/ITCI
- Options chain: https://www.quantisnow.com/options/ITCI
- SEC 8-K filings only: https://www.quantisnow.com/company/ITCI/8-k
- RSS and alerts for ITCI: https://www.quantisnow.com/docs/rss-feeds.md
